Psychedelic Stocks: MindMed and atai Slash their Pipelines, Mydecine Collapses
The psychedelic renaissance hits a rough patch as major companies look to tighten their belts or face total collapse. What’s happening with Psychedelic Stocks?
Author: James Hallifax
Chris Rock Really Likes Psychedelics
The comedian openly discusses using psychedelic mushrooms and hosting ayahuasca ceremonies at his home
California’s Cowardly Politicians Gut Psychedelic Decriminalization Bill
The California legislature had the power to act on psychedelic decriminalization, but instead decided to continue the War on Drugs
MindMed Shelves 18-MC for Opioid Use Disorder and Further Cuts Pipeline
MindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is going on with this psychedelics company?
An Inside Look into Field Trip’s Next-Generation Psychedelic, FT-104
Field Trip is the only company exploring the therapeutic potential of a 4-HO-DiPT prodrug called FT-104. But how does it work?
Compass Pathways Sued for Stealing Trade Secrets
Compass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual property
Three Phase 3 Clinical Trials that Could Legalize Psychedelics
The road to psychedelic legalization has many paths. These 3 clinical trials have the best chances to legalize psychedelics for therapy
How to Smoke DMT for Beginners in 5 Easy Steps
People who smoke DMT describe an intense and profound psychedelic experience, but there’s a trick to getting the most out of each hit
The Top 5 Psychedelics Podcasts
New psychedelic podcasts are popping up every week, but which ones are worth listening to? Here’s a few of our favorites.
The Real Reason Cybin Bought Entheon’s DMT Clinical Trial
In a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical. CEO Doug Drysdale explains why in a Reddit AMA
End of content
End of content